XPENG-MOTORS
14.3.2022 14:34:04 CET | Business Wire | Press release
XPENG, a leading smart electric vehicle and mobility technology company, today announced that it has joined three major European automobile associations, the European Association for Electromobility (AVERE), Royal RAI Vereniging / RAI Association (RAI) and BIL Sweden, underlining the company's long-term commitment to developing the smart and greener mobility ecosystem in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005486/en/
Leveraging its strong expertise in innovative technology and sustainable mobility, XPENG will bring valuable insights in the smart EV sector, contributing to the development and implementation of the European Commission's Sustainable and Smart Mobility Strategy.
“We appreciate the extraordinary commitment that Europe has made to carbon neutrality and sustainable mobility,” said Leon He, Vice President of XPENG. “Our vision is to transform future mobility with technology. By consolidating our industry connections and actively engaging with the European automobile sector, we hope to accelerate the development of electrification, digitization and automation technologies for the auto sector. XPENG will continue to invest in innovations and is excited to work together with automobile stakeholders in Europe to achieve our shared vision: building a sustainable mobility ecosystem for the future.”
AVERE is the leading European association that promotes electromobility and sustainable transport across Europe. It represents and advocates for electromobility on behalf of the industry, academia, and EV users at both EU and national levels.
“We at AVERE are delighted to welcome XPENG as a member as it continues to develop and invest in Europe,” said Philippe Vangeel, Secretary-General of AVERE. “We look forward to engaging and working together with XPENG in shaping the future of smart and sustainable mobility.”
The Royal RAI Vereniging represents the interests of enterprises in the mobility sector in the Netherlands, and plays an active role in facilitating the production and sales of vehicles and parts for its 700 members, who together supply all forms of road transportation.
Steven van Eijck, Chairman of the Royal RAI Vereniging, commented: “We are very happy to welcome XPENG as our new member. XPENG plays an important role in the rapidly growing market for electric mobility, particularly passenger cars in the world. This is essential as we transition towards a zero-emission mobility system to meet our environmental and climate goals. The Dutch passenger car market is leading the initiatives in Europe when it comes to electrification. It acts as a gateway to the European passenger car market and is therefore attractive for newcomers.”
BIL Sweden is the Swedish industry organization for manufacturers and importers of cars, trucks and buses. The member companies together account for around 97 percent of new car sales in Sweden. The organization acknowledges that vehicles are a key player in the sustainable society focused on climate and environmental issues, safety and mobility development. BIL Sweden's vision for the year 2030: building long-term sustainable mobility and transportation solutions.
"BIL Sweden aims to work for a society that achieves its climate goals through developing long-term carbon-neutral strategies that promote energy efficiency and renewable energy vehicles. We believe that fossil fuels can be gradually phased out and replaced with renewable fuels and electrification as we improve energy efficiency. We are confident that companies like XPENG, which are focused on electric power, technology and innovation, are well positioned to contribute to this development. I am really looking forward to having them in BIL Sweden," said Mattias Bergman, CEO of BIL Sweden.
Earlier, XPENG announced the opening of its first European Experience Stores in Sweden and the Netherlands, and its partnership with Bilia and Emil Frey Nederland NV to build a first-class distribution, sales and service network in Sweden and the Netherlands, respectively.
The company is committed to Europe’s carbon-neutral initiatives and is dedicated to building intelligent, sustainable and people-first mobility solutions. XPENG differentiates itself with its full-stack in-house Advanced Driver Assistance System (ADAS) technologies and in-car intelligent operating system, as well as core vehicle systems including powertrain and electrification/electronic architecture, providing superior and safe mobility experience a growing base of customers.
About XPENG
https://heyxpeng.com/
About AVERE
https://www.avere.org/what-is-avere/
About Royal RAI Vereniging / RAI Association
https://www.raivereniging.nl/automotiveindustrynl/over-ons
About BIL Sweden
https://www.bilsweden.se/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005486/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom